This Phase 2/3 study aims to:
Demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.
Demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of the first episode of virologically confirmed moderate to severe cases of COVID-19 in SARS-CoV-2 naïve participants.